Sinobot X1 Neurosurgical Robot

The Sinobot X1 (also designated SR1-3D) represents a breakthrough in neurosurgical robotics as the world’s first system employing 3D structured light registration technology. Developed by Sinovation through over two decades of collaborative research with Tsinghua University, this robot eliminates traditional marker-based registration while achieving sub-millimeter positioning accuracy for stereotactic procedures.

Product Overview

The Sinobot X1 addresses fundamental limitations of conventional neurosurgical robots by replacing marker-based optical registration with Holoshot 3D structured light sensing. This approach fundamentally reimagines patient registration, reducing preparation time from hours to under 3 minutes while eliminating the need for scalp markers and additional CT scanning.

The system received NMPA approval through China’s Special Review Channel for Innovative Medical Devices in 2018, followed by FDA 510(k) clearance in June 2023 (K220072), making it the only Chinese-developed neurosurgical robot with FDA authorization. This dual regulatory achievement positions Sinovation for both domestic market leadership and international expansion.

Key Features

Sinobot X1’s Holoshot 3D structured light registration completes markerless patient setup in under 3 minutes, eliminating the additional CT scans required by conventional neurosurgical robots.

• Holoshot 3D Structured Light Registration: Automatic visual scanning of the patient’s facial surface establishes spatial coordination without markers. The robotic arm itself serves as the positioning reference, eliminating light path occlusion issues associated with external tracking systems.

• Intelligent Environment Modeling: The system automatically scans and models the skull and surrounding environment, enabling autonomous calculation of optimal obstacle avoidance paths for safe, efficient positioning.

• AngioRender Vascular Avoidance: Proprietary 3D vascular visualization technology provides multidimensional views of intracranial vessels, minimizing hemorrhage risk during electrode implantation.

• SurgeonEye Superposition Technology: Enhanced visualization overlays vascular structures on surgical planning views, enabling confident trajectory planning in complex vascular territories.

• 6-DOF Robotic Arm: Full six degrees of freedom enable optimal positioning for diverse surgical approaches and patient positions without workspace interference.

• Force Feedback Monitoring: High-precision pressure sensors with specialized algorithms provide real-time force monitoring through a closed-loop control system.

Technical Specifications

Cleared by FDA in June 2023 and NMPA-approved since 2018, Sinobot X1 achieves sub-millimeter stereotactic accuracy using 3D structured light registration without fiducial markers.

Clinical Applications

The Sinobot X1 supports a broad range of stereotactic neurosurgical procedures:

Epilepsy (SEEG): The system excels in stereoelectroencephalography electrode implantation, where multiple electrodes (often 10 or more) must be placed with precision. Robotic assistance reduces implantation time by over 60% compared to frame-based techniques while improving accuracy and stability across multiple insertions.

Parkinson’s Disease: Deep brain stimulation (DBS) electrode placement benefits from the robot’s precise targeting capabilities, enabling advance surgical decision-making and accurate localization of subthalamic nucleus or globus pallidus targets.

Brain Tumor Biopsy: The frameless system enables biopsy approaches from various directions and angles, eliminating the discomfort of stereotactic frame installation while maintaining diagnostic accuracy.

Cerebral Hemorrhage: Stereotactic aspiration for hematoma evacuation provides a safe, effective approach for patients with spontaneous intracerebral hemorrhage, with the robotic system enabling bedside or emergency department deployment.

Trigeminal Neuralgia: Percutaneous procedures benefit from the robot’s precise trajectory planning and stable positioning during needle advancement.

Regulatory Status

Frequently Asked Questions

What makes Sinobot X1 different from other neurosurgical robots?

The Sinobot X1 is the world’s first neurosurgical robot using 3D structured light registration technology. Unlike systems requiring fiducial markers and additional CT scanning, Holoshot technology performs automatic facial surface scanning to establish patient registration in under 3 minutes without markers.

What is the positioning accuracy of Sinobot X1?

The system achieves sub-millimeter positioning accuracy, meeting the precision requirements of stereotactic neurosurgery including SEEG electrode implantation and DBS procedures.

Is Sinobot X1 FDA approved?

Yes. The Sinobot X1 received FDA 510(k) clearance in June 2023 (K220072), making it the first and only Chinese-developed neurosurgical robot with FDA authorization.

How many hospitals use Sinobot X1?

Sinovation’s neurosurgical robots are deployed in over 100 tertiary hospitals across China, with the company serving more than 200 medical institutions through its complete product portfolio.